----

----

| Delaware                                                      |   | 06-1123096                          |
|---------------------------------------------------------------|--------|-------------------------------------|
| (State or other jurisdiction ofincorporation or organization) |   | (I.R.S. employeridentification no.) |

----

----

| PART I     | Financial Information                                                                              | Page No. |
|------------|----------------------------------------------------------------------------------------------------|----------|
|       |                                                                                               |     |
| Item 1     | Financial Statements (Unaudited)                                                                   |     |
|       |                                                                                               |     |
|       | Condensed Consolidated Balance Sheets as of March 31, 2011and December 31, 2010                    | 3        |
|       |                                                                                               |     |
|       | Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2011 and 2010 | 5        |
|       |                                                                                               |     |
|       | Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2011 and 2010 | 6        |
|       |                                                                                               |     |
|       | Notes to Condensed Consolidated Financial Statements                                               | 7        |
|       |                                                                                               |     |
| Item 2     | Management’s Discussion and Analysis of Financial Condition and Results of Operations        | 12       |
|       |                                                                                               |     |
| Item 3     | Quantitative and Qualitative Disclosures about Market Risk                                         | 15       |
|       |                                                                                               |     |
| Item 4     | Controls and Procedures                                                                            | 15       |
|       |                                                                                               |     |
|       |                                                                                               |     |
|       |                                                                                               |     |
| PART II    | Other Information                                                                                  |     |
|       |                                                                                               |     |
| Item 1     | Legal Proceedings                                                                                  | 16       |
|       |                                                                                               |     |
| Item 6     | Exhibits                                                                                           | 16       |
|       |                                                                                               |     |
| Signatures |                                                                                               | 17       |
|       |                                                                                               |     |

----

|                                      |   | March 31,  |          |   | December 31, |   |
|-------------------------------------------|--------|-----------------|---------------|--------|--------------|--------|
| Assets                                    |   | 2011            |          |   | 2010         |   |
|                                      |   |            |          |   |         |   |
| Current assets:                           |   |            |          |   |         |   |
| Cash and cash equivalents                 |   | $               | 2,200,963     |   |         | $      | 4,492,690 |   |
| Accounts receivable, net of allowance     |   |            | 3,178,525     |   |         |   | 2,606,616 |   |
| Recoverable income taxes                  |   |            | -             |   |         |   | 13,655 |   |
| Inventories                               |   |            | 4,834,243     |   |         |   | 4,812,965 |   |
| Other current assets                      |   |            |  344,377 |   |         |   |  310,187 |   |
| Total current assets                      |   |            | 10,558,108    |   |         |   | 12,236,113 |   |
|                                      |   |            |          |   |         |   |   |   |
| Property and equipment:                   |   |            |          |   |         |   |   |   |
| Leasehold improvements                    |   |            | 252,517       |   |         |   | 252,517 |   |
| Equipment at customers                    |   |            | 1,856,346     |   |         |   | 1,686,919 |   |
| Machinery and equipment                   |   |            | 4,883,287     |   |         |   |  5,114,460 |   |
|                                      |   |            | 6,992,150     |   |         |   | 7,053,896 |   |
| Accumulated depreciation and amortization |   |            | (5,143,892    | )      |         |   | (5,244,819 | ) |
| Property and equipment, net               |   |            | 1,848,258     |   |         |   | 1,809,077 |   |
|                                      |   |            |          |   |         |   |   |   |
| Intangible and other assets, net          |   |            | 674,616       |   |         |   | 651,626 |   |
|                                      |   |            |          |   |         |   |   |   |
| Total assets                              |   | $               | 13,080,982    |   |         | $      | 14,696,816 |   |

----

| Liabilities and Stockholders’ Equity                            |   | March 31, |       |   | December 31, |   |
|-----------------------------------------------------------------------|--------|-----------|------------|--------|--------------|--------|
|                                                                  |   | 2011      |       |   | 2010         |   |
| Current liabilities:                                                  |   |      |       |   |         |   |
| Accounts payable                                                      |   | $         | 1,518,404  |   |         | $      | 2,283,906 |   |
| Accrued expenses                                                      |   |      | 1,083,463  |   |         |   |  909,331 |   |
| Total current liabilities                                             |   |      | 2,601,867  |   |         |   | 3,193,237 |   |
|                                                                  |   |      |       |   |         |   |   |   |
|                                                                  |   |      |       |   |         |   |   |   |
| Deferred gain on sale and leaseback of property                       |   |      | 865,767    |   |         |   | 899,426 |   |
| Income taxes payable                                                  |   |      | 211,159    |   |         |   | 211,159 |   |
| Total liabilities                                                     |   |      | 3,678,793  |   |         |   | 4,303,822 |   |
|                                                                  |   |      |       |   |         |   |   |   |
| Commitments and Contingencies                                         |   |      |       |   |         |   |   |   |
|                                                                  |   |      |       |   |         |   |   |   |
| Stockholders' equity:                                                 |   |      |       |   |         |   |   |   |
| Preferred stock, $.001 par value per share, 1,000,000                 |   |      |       |   |         |   |   |   |
|    shares authorized, no shares issued or outstanding  |   |      | —    |   |         |   | — |   |
| Common stock, $.004 par value per share, 40,000,000                   |   |      |       |   |         |   |   |   |
|    shares authorized, 13,633,883 and 13,575,401 shares |   |      |       |   |         |   |   |   |
|    issued at March 31, 2011 and December 31, 2010,     |   |      |       |   |         |   |   |   |
|    respectively, including shares held in treasury     |   |      | 54,536     |   |         |   | 54,302 |   |
| Common stock held in treasury, at cost - 86,000 shares                |   |      | (101,480   | )      |         |   | (101,480 | ) |
| Additional paid-in capital                                            |   |      | 10,217,492 |   |         |   | 10,002,600 |   |
| Retained earnings                                                     |   |      | (768,359   | )      |         |   |  437,572 |   |
| Total stockholders' equity                                            |   |      | 9,402,189  |   |         |   |  10,392,994 |   |
|                                                                  |   |      |       |   |         |   |   |   |
| Total liabilities and stockholders' equity                            |   | $         | 13,080,982 |   |         | $      | 14,696,816 |   |

----

|                                                               |   | Three Months Ended |            |
|--------------------------------------------------------------------|--------|--------------------|-----------------|
|                                                               |   | March 31,          |            |
|                                                               |   | 2011               |            |   | 2010 |   |
|                                                               |   |               |            |   |   |   |
| Net sales                                                          |   | $                  | 5,643,124       |   |   | $ | 6,108,444 |   |
|                                                               |   |               |            |   |   |   |   |   |
| Cost of sales                                                      |   |               |  3,508,570 |   |   |   |  3,454,178 |   |
| Gross profit                                                       |   |               | 2,134,554       |   |   |   | 2,654,266 |   |
|                                                               |   |               |            |   |   |   |   |   |
| Operating expenses:                                                |   |               |            |   |   |   |   |   |
| Research and development                                           |   |               | 712,344         |   |   |   | 463,677 |   |
| Selling, general and administrative                                |   |               |  2,690,843 |   |   |   |  2,119,760 |   |
|                                                               |   |               |  3,403,187 |   |   |   |  2,583,437 |   |
|                                                               |   |               |            |   |   |   |   |   |
| Operating (loss) income                                            |   |               | (1,268,633      | ) |   |   | 70,829 |   |
|                                                               |   |               |            |   |   |   |   |   |
| Other (income) expense, net                                        |   |               |  (2,562    | ) |   |   |  25,003 |   |
|                                                               |   |               |            |   |   |   |   |   |
| (Loss) income from continuing operations before income taxes       |   |               | (1,266,071      | ) |   |   | 45,826 |   |
|                                                               |   |               |            |   |   |   |   |   |
| Income tax (benefit) expense                                       |   |               |  (20,448   | ) |   |   | 6,946 |   |
|                                                               |   |               |            |   |   |   |   |   |
| (Loss) income from continuing operations                           |   |               | (1,245,623      | ) |   |   | 38,880 |   |
| Income from discontinued operations, net of income taxes           |   |               | 39,692          |   |   |   |  168,642 |   |
| Net (loss) income:                                                 |   | $                  | (1,205,931      | ) |   | $ | 207,522 |   |
|                                                               |   |               |            |   |   |   |   |   |
| (Loss) income per common share from continuing operations -Basic   |   | $                  | (0.10           | ) |   | $ | 0.00 |   |
| Diluted                                                            |   | $                  | (0.10           | ) |   | $ | 0.00 |   |
|                                                               |   |               |            |   |   |   |   |   |
| Income per common share from discontinued operations -Basic        |   | $                  | 0.01            |   |   | $ | 0.02 |   |
|     Diluted                                         |   | $                  | 0.01            |   |   | $ | 0.02 |   |
|                                                               |   |               |            |   |   |   |   |   |
| Net (loss) income per common share –    Basic |   | $                  | (0.09           | ) |   | $ | 0.02 |   |
|     Diluted                                         |   | $                  | (0.09           | ) |   | $ | 0.02 |   |
|                                                               |   |               |            |   |   |   |   |   |
| Weighted average number of common shares outstanding:              |   |               |            |   |   |   |   |   |
| Basic                                                              |   |               | 13,011,198      |   |   |   | 11,343,363 |   |
| Diluted                                                            |   |               | 13,011,198      |   |   |   | 12,246,955 |   |

----

|                                                                                                                                                                                               |   | Three Months Ended |            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------------|-----------------|
|                                                                                                                                                                                               |   | March 31,          |            |
|                                                                                                                                                                                               |   | 2011               |            |   | 2010 |   |
| OPERATING ACTIVITIES:                                                                                                                                                                              |   |               |            |   |   |   |
| Cash flow from operating activities                                                                                                                                                                |   |               |            |   |   |   |
| Net (loss) income                                                                                                                                                                                  |   | $                  | (1,205,931      | ) |   | $ | 207,522 |   |
| Less income from discontinued operations                                                                                                                                                           |   |               |  39,692    |   |   |   |  168,642 |   |
| (Loss) income from continuing operations                                                                                                                                                           |   |               | (1,245,623      | ) |   |   | 38,880 |   |
|     Adjustments to reconcile net (loss) income  from continuing operations to      net cash (used in) provided by operating activities |   |               |            |   |   |   |   |   |
| Depreciation and amortization                                                                                                                                                                      |   |               | 245,099         |   |   |   | 234,276 |   |
| Stock compensation                                                                                                                                                                                 |   |               | 210,189         |   |   |   | 19,267 |   |
| Amortization of gain on sale and leaseback                                                                                                                                                         |   |               | (33,659         | ) |   |   | (33,660 | ) |
| Deferred income taxes                                                                                                                                                                              |   |               | (20,448         | ) |   |   | — |   |
| Changes in operating assets and liabilities:                                                                                                                                                       |   |               |            |   |   |   |   |   |
| Accounts receivable                                                                                                                                                                                |   |               | (571,909        | ) |   |   | (186,293 | ) |
| Inventories                                                                                                                                                                                        |   |               | (21,278         | ) |   |   | 615,195 |   |
| Other current assets                                                                                                                                                                               |   |               | (34,190         | ) |   |   | 67,358 |   |
| Accounts payable and accrued expenses                                                                                                                                                              |   |               | (591,370        | ) |   |   | 192,707 |   |
| Income taxes payable                                                                                                                                                                               |   |               |  13,655    |   |   |   |  33,577 |   |
| Net cash (used in) provided by operating activities of continuing operations                                                                                                                       |   |               | (2,049,534      | ) |   |   |  981,307 |   |
|                                                                                                                                                                                               |   |               |            |   |   |   |   |   |
| INVESTING ACTIVITIES:                                                                                                                                                                              |   |               |            |   |   |   |   |   |
| Expenditures for property and equipment                                                                                                                                                            |   |               | (237,120        | ) |   |   | (12,840 | ) |
| Purchase of intangible assets                                                                                                                                                                      |   |               |  (70,150   | ) |   |   |  (28,359 | ) |
| Net cash used by investing activities of continuing operations                                                                                                                                     |   |               | (307,270        | ) |   |   |  (41,199 | ) |
|                                                                                                                                                                                               |   |               |            |   |   |   |   |   |
| FINANCING ACTIVITIES:                                                                                                                                                                              |   |               |            |   |   |   |   |   |
| Repayments of notes payable                                                                                                                                                                        |   |               | —         |   |   |   | (50,678 | ) |
| Repayments under line-of-credit                                                                                                                                                                    |   |               | —         |   |   |   | (694,657 | ) |
| Repayments of long term debt                                                                                                                                                                       |   |               | —         |   |   |   | (159,707 | ) |
| Deferred financing costs                                                                                                                                                                           |   |               | —         |   |   |   | (111,369 | ) |
| Proceeds from issuance of common stock                                                                                                                                                             |   |               | 4,937           |   |   |   |  11,777 |   |
| Net cash provided by (used in) financing activities of continuing operations                                                                                                                       |   |               | 4,937           |   |   |   | (1,004,634 | ) |
|                                                                                                                                                                                               |   |               |            |   |   |   |   |   |
| Net cash used in continuing operations                                                                                                                                                        |   |               | (2,351,867      | ) |   |   |  (64,526 | ) |
| Cash flows from discontinued operations                                                                                                                                                            |   |               |            |   |   |   |   |   |
| Cash provided by operating activities of discontinued operations                                                                                                                                   |   |               |  60,140    |   |   |   |  526,353 |   |
| Net cash provided by discontinued operations                                                                                                                                                       |   |               |  60,140    |   |   |   |  526,353 |   |
| Net change in cash and cash equivalents                                                                                                                                                            |   |               | (2,291,727      | ) |   |   | 461,827 |   |
| Cash and cash equivalents, beginning of period                                                                                                                                                     |   |               |  4,492,690 |   |   |   |  1,186,779 |   |
| CASH AND CASH EQUIVALENTS, END OF PERIOD                                                                                                                                                           |   | $                  | 2,200,963       |   |   | $ | 1,648,606 |   |
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION                                                                                                                                                  |   |               |            |   |   |   |   |   |
| Cash paid during the period for interest                                                                                                                                                           |   | $                  | —         |   |   | $ | 50,927 |   |
| Cash paid during the period for income taxes, net                                                                                                                                                  |   | $                  | —         |   |   | $ | 3,500 |   |

----

|                                                                                    |   | March 31,2011 |          |   | December 31,2010 |   |
|-----------------------------------------------------------------------------------------|--------|---------------|---------------|--------|------------------|--------|
|                                                                                    |   |          |          |   |             |   |
|             Raw materials   |   | $             | 3,878,768     |   |             | $      | 3,733,550 |   |
|             Work in process |   |          | 9,996         |   |             |   | 2,950 |   |
|             Finished goods  |   |          |  945,479 |   |             |   |  1,076,465 |   |
|                                                                                    |   | $             | 4,834,243     |   |             | $      | 4,812,965 |   |

----

|                     |   | March 31, |          |   | December 31, |   |
|--------------------------|--------|-----------|---------------|--------|--------------|--------|
|                     |   | 2011      |          |   | 2010         |   |
|                     |   |      |          |   |         |   |
| Patents and other assets |   | $         | 648,289       |   |         | $      | 593,166 |   |
| Patents pending          |   |      | 260,002       |   |         |   | 254,975 |   |
| Purchased technology     |   |      | 46,026        |   |         |   | 46,026 |   |
| Deferred finance charges |   |      |  180,205 |   |         |   |  170,205 |   |
|                     |   |      | 1,134,522     |   |         |   | 1,064,372 |   |
| Accumulated amortization |   |      | (459,906      | )      |         |   |  (412,746 | ) |
|                     |   | $         | 674,616       |   |         | $      | 651,626 |   |

| 2012   |   | $      | 56,000  |   |
|--------|--------|--------|---------|--------|
| 2013   |   |   | 40,000  |   |
| 2014   |   |   | 18,000  |   |
| 2015   |   |   | 14,000  |   |
| 2016   |   |   | 14,000  |   |
|   |   | $      | 142,000 |   |

| ·   | Tissue oximetry monitoring products – includes sales of the FORE-SIGHT® cerebral monitors, sensors and accessories. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------|

| ·   | Traditional monitoring products includes: |
|--------------------|-------------------------------------------|

| 1)   | Vital signs bedside monitors and accessories incorporating various combinations of measurement parameters for both human and veterinary use. Parameters found in these monitors include the Company’s proprietary MAXNIBP® non-invasive blood pressure, pulse oximetry, electro-cardiography, temperature, and capnography. |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2)   | Blood pressure measurement technology – includes sales to OEM manufacturers of the Company’s proprietary MAXNIBP non-invasive blood pressure technology, sold as a discrete module to be included in the OEM customers own multi-parameter monitors, and related license fees. |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3)   | Supplies and service – includes sales of neonatal intensive care supplies including electrodes and skin temperature probes, and service repair. |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|                                                    |   | March 31,2011 |         |   | March 31,2010 |   |
|---------------------------------------------------------|--------|---------------|--------------|--------|---------------|--------|
|                                                    |   |          |         |   |          |   |
| Revenues                                                |   | $             | —      |   |          | $      | 2,386,588 |   |
| Cost of products sold                                   |   |          | —      |   |          |   | 2,084,874 |   |
| Gross profit                                            |   |          | —      |   |          |   | 301,714 |   |
| Operating expenses                                      |   |          | —      |   |          |   | 78,874 |   |
| Interest expense                                        |   |          | —      |   |          |   | 24,067 |   |
| Other income                                            |   |          | 60,140       |   |          |   | — |   |
| Income from discontinued operations before income taxes |   |          | 60,140       |   |          |   | 198,773 |   |
| Income tax expense                                      |   |          |  20,448 |   |          |   |  30,131 |   |
| Income from discontinued operations                     |   | $             | 39,692       |   |          | $      | 168,642 |   |

|                                                                                                                                                |   | Three Months Ended |       |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------------|------------|
|                                                                                                                                                |   | March 31,          |       |
|                                                                                                                                                |   | 2011               |       |   | 2010 |   |
| Weighted average shares outstanding, net of unvested restricted common shares –  used to compute basic income (loss) per share |   |               | 13,011,198 |   |   |   | 11,343,363 |   |
|                                                                                                                                                |   |               |       |   |   |   |   |   |
| Dilutive effect of unvested restricted common shares, and outstanding warrants and options                                                          |   |               | —    |   |   |   | 903,592 |   |
|                                                                                                                                                |   |               |       |   |   |   |   |   |
| Weighted average shares of dilutive securities outstanding – used to compute diluted income (loss) per share                             |   |               | 13,011,198 |   |   |   | 12,246,955 |   |

----

|                                          |   |   |      |   |             |   |   | Aggregate |   |   | Weighted-Average   |   |
|-----------------------------------------------|--------|--------|-----------|--------|------------------|--------|--------|-----------|--------|--------|--------------------|--------|
|                                          |   | Option |      |   | Weighted-Average |   |   | Intrinsic |   |   | Contractual Life   |   |
|                                          |   | Shares |      |   | Exercise Price   |   |   | Value (1) |   |   | Remaining in Years |   |
|                                          |   |   |      |   |             |   |   |      |   |   |               |   |
| Outstanding at December 31, 2010              |   |   | 935,875   |   |             | $      | 2.29   |      |   | $      | 877,788            |   |   |   | 7.3 |   |
| Granted                                       |   |   | 200,000   |   |             |   | 3.16   |      |   |   |               |   |   |   |   |   |
| Cancelled                                     |   |   | (16,667   | )      |             |   | 3.49   |      |   |   |               |   |   |   |   |   |
| Exercised                                     |   |   | (300      | )      |             |   | 1.50   |      |   |   |               |   |   |   |   |   |
| Outstanding at March 31, 2011                 |   |   | 1,118,908 |   |             | $      | 2.45   |      |   | $      | 922,647            |   |   |   | 7.6 |   |
| Exercisable at March 31, 2011                 |   |   | 418,614   |   |             | $      | 2.34   |      |   | $      | 494,540            |   |   |   | 4.4 |   |
| Vested and expected to vest at March 31, 2011 |   |   | 1,109,628 |   |             | $      | 2.45   |      |   | $      | 915,988            |   |   |   | 7.6 |   |

----

|                               |   |  Three MonthsEndedMarch 31, 2011 |          |   | WeightedAverageGrant DateFair-Value |   |   |  Twelve MonthsEndedDecember 31, 2010 |   |   | WeightedAverageGrant DateFair-Value |   |
|------------------------------------|--------|---------------------------------------|---------------|--------|-------------------------------------|--------|--------|-------------------------------------------|--------|--------|-------------------------------------|--------|
|                               |   |                                  |          |   |                                |   |   |                                      |   |   |                                |   |
| Outstanding at beginning of period |   |                                  | 484,070       |   |                                | $      | 1.87   |                                      |   |   | 190,265                             |   |   | $ | 2.56 |   |
| Granted                            |   |                                  | 60,000        |   |                                |   | 3.12   |                                      |   |   | 451,222                             |   |   |   | 2.04 |   |
| Cancelled                          |   |                                  | (3,334        | )      |                                |   | 2.09   |                                      |   |   | (18,501                             | )      |   |   | 1.85 |   |
| Vested                             |   |                                  |  (16,112 | )      |                                |   | 2.42   |                                      |   |   |  (138,916                      | )      |   |   | 2.56 |   |
| Outstanding at end of period       |   |                                  | 524,624       |   |                                | $      | 2.32   |                                      |   |   | 484,070                             |   |   | $ | 1.87 |   |

----

| ($000’s)                               |   | Three Months Ended |        |   | Three Months Ended |   |        | Increase/  |   |
|----------------------------------------------|--------|--------------------|-------------|--------|--------------------|--------|-------------|------------|--------|
|                                         |   | March 31, 2011     |        |   | March 31, 2010     |   |        | (Decrease) |   |
|                                         |   |               |        |   |               |   |        |       |   |
| Traditional Vital Signs Monitoring           |   | $                  | 4,053       |   |               | $      | 4,581       |       |   | $ | (528 | ) |
| Tissue Oximetry Monitoring                   |   |               |  1,562 |   |               |   |  1,364 |       |   |   |  198 |   |
|                                         |   |               | 5,615       |   |               |   | 5,945       |       |   |   | (330 | ) |
| Discontinued Products – Apnea/Analogic |   |               | 28          |   |               |   |  163   |       |   |   |  (135 | ) |
|                                         |   | $                  | 5,643       |   |               | $      | 6,108       |       |   | $ | (465 | ) |
|                                         |   |               |        |   |               |   |        |       |   |   |   |   |
| Domestic Sales                               |   | $                  | 4,058       |   |               | $      | 3,940       |       |   | $ | 118 |   |
| International Sales                          |   |               | 1,585       |   |               |   |  2,168 |       |   |   |  (583 | ) |
|                                         |   | $                  | 5,643       |   |               | $      | 6,108       |       |   | $ | (465 | ) |

----

| ($000’s)                   |   | Three Months Ended |   |   | Three Months Ended |   |      | Increase/  |   |
|----------------------------------|--------|--------------------|--------|--------|--------------------|--------|-----------|------------|--------|
|                             |   | March 31, 2011     |   |   | March 31, 2010     |   |      | (Decrease) |   |
|                             |   |               |   |   |               |   |      |       |   |
| Monitors & Accessories Sales |   | $                  | 393    |   |               | $      | 625       |       |   | $ | (232 | ) |
| Sensors Sales                    |   |               | 1,169  |   |               |   |  739 |       |   |   |  430 |   |
|                             |   | $                  | 1,562  |   |               | $      | 1,364     |       |   | $ | 198 |   |

| Domestic Sales      |   | $      | 926       |   |   | $      | 691       |   |   | $      | 235       |   |
|---------------------|--------|--------|-----------|--------|--------|--------|-----------|--------|--------|--------|-----------|--------|
| International Sales |   |   |  636 |   |   |   |  673 |   |   |   |  (37 | )      |
|                |   | $      | 1,562     |   |   | $      | 1,364     |   |   | $      | 198       |   |

----

----

----

|   | 10.1  | Employment agreement with Matthew J. Herwig dated January 7, 2011 “(Incorporated by reference to the Company’s Form 8-K filed on January 10, 2011)” |
|--------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 10.2  | Inducement Non-Qualified Stock Option Agreement with Matthew J. Herwig dated January 7, 2011 (“Incorporated by reference to the Company’s Form 8-K filed on January 10, 2011)” |
|--------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 10.3  | Inducement Restricted Stock Agreement with Matthew J. Herwig dated January 7, 2011 (“Incorporated by reference to the Company’s Form 8-K filed on January 10, 2011)” |
|--------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 31.1  | Certification pursuant to Rule 13a-14(a) of Thomas M. Patton, President and Chief Executive Officer |
|--------|------------|-----------------------------------------------------------------------------------------------------|

|   | 31.2  | Certification pursuant to Rule 13a-14(a) of Jeffery A. Baird, Chief Financial Officer |
|--------|------------|---------------------------------------------------------------------------------------|

|   | 32.1 | Certification pursuant to 18 U.S.C. 1350 of Periodic Financial Report of Thomas M. Patton, President and Chief Executive Officer and Jeffery A. Baird, Chief Financial Officer |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|                                                                                   |                          |
|----------------------------------------------------------------------------------------|-------------------------------|
| /s/ Thomas M. Patton                                                              | Date:  May 11, 2011 |
| By:  Thomas M. Patton                                                        |                          |
|          President and Chief Executive Officer |                          |
|                                                                                   |                          |

|                                                               |                          |
|--------------------------------------------------------------------|-------------------------------|
| /s/ Jeffery A. Baird                                          | Date:  May 11, 2011 |
| By:  Jeffery A. Baird                                    |                          |
|         Chief Financial Officer |                          |
|                                                               |                          |

----